Abstract 613P
Background
Physicians have frequent interactions with the pharmaceutical industry (pharma), however, there is concern for possible corporate influence on physicians’ prescribing behaviours. We sought to understand perceptions and interactions between pharma and medical oncologists (MO), in comparison with infectious diseases (ID) physicians.
Methods
We conducted an anonymous online cross-sectional survey of Australian MO and ID physicians comparing self-reported interactions and attitudes with pharma. An additional survey was undertaken at Tan Tock Seng Hospital, Singapore.
Results
A total of 204 Australian and Singaporean physicians were surveyed including 102 oncologists and 102 ID physicians. Demographics including age, gender and years of practice between the two Australian specialties were similar, with an exception that most ID physicians had mainly public work (95% vs. 78% for oncologists, p<0.001). Oncologists had more frequent contact with pharma, the majority (69%) negotiating compassionate access for patients on a monthly/annual basis, compared with ID physicians who had never done so (45%), p<0.001. More ID physicians had never attended a sponsored meeting (15% ID vs. 27% MO respectively, p=0.01) or received travel/accommodation grants from pharma (42% ID vs. 85% MO respectively, p<0.001). However, most physicians (92%) had never received gifts from pharma, with no difference between groups (p=0.17). Most Australian oncologists believed that interacting with pharma was overall beneficial for patient care (78%) compared to ID physicians (34%, p<0.001). This statement was shared by 71% of Singaporean oncologists. Similar rates of Australian oncologists and ID physicians (83% vs. 88%, respectively) felt comfortable for patients to know the details of their interactions with pharma, however, only 57% of Singaporean oncologists agreed with this statement. Most Australian respondents (77%) agreed that there was strong public skepticism of these interactions (p=0.35).
Conclusions
Medical oncologists had more interactions with pharma than ID physicians and were more likely to believe that this was overall beneficial to patient care despite the negative public perception associated with this.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
P.L. Chia: Financial Interests, Personal, Advisory Board: Merck, Roche, Pfizer, Amgen; Financial Interests, Institutional, Research Funding: Merck, Roche, Pfizer, Amgen. T. John: Financial Interests, Personal, Invited Speaker, Speaker tour Vietnam: AstraZeneca; Financial Interests, Personal, Invited Speaker, CTIO: Merck Sharp Dohme; Financial Interests, Personal, Advisory Board: BMS, AstraZeneca, Bayer, Specialised Therapeutics; Financial Interests, Institutional, Advisory Board: Roche, Novartis, Pfizer, Amgen, Takeda, PharmaMar; Financial Interests, Personal, Other, Speaker/Chair: ACE Oncology. All other authors have declared no conflicts of interest.
Resources from the same session
451P - The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia
Presenter: Daisuke Arai
Session: Poster Display
Resources:
Abstract
452P - The relationship between BCG immunotherapy and oxidative stress parameters in patients with non-muscle invasive bladder cancer
Presenter: Mukul Singh
Session: Poster Display
Resources:
Abstract
453P - Palonosetron plus megestrol acetate verses palonosetron plus dexamethasone in preventing moderately emetogenic chemotherapy-induced nausea and vomiting: A randomized, multicenter, crossover, phase II trial
Presenter: Qiaoqi Li
Session: Poster Display
Resources:
Abstract
454P - A multicenter randomized open-label phase II study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study
Presenter: Akira Ooki
Session: Poster Display
Resources:
Abstract
455P - Assessing model-predicted neurokinin-1 (NK1) receptor occupancy (RO) of netupitant to support efficacy over an extended time period
Presenter: Matti Aapro
Session: Poster Display
Resources:
Abstract
456P - Oxycodone/naloxone in moderate-to-severe cancer pain: A phase III study in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
457P - Anticoagulation for terminal cancer patients with cancer associated venous thromboembolism
Presenter: Sang Bo Oh
Session: Poster Display
Resources:
Abstract
458P - Association between TSPAN15 and SLC44A2 genetic polymorphisms and venous thromboembolism in cancer patients
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
459P - Association between national health screening program and undertreatment of dyslipidemia in cancer survivors: A cross-sectional study
Presenter: Sujeong Shin
Session: Poster Display
Resources:
Abstract
460P - Group to grow: A systematic review of group-based interventions for post-traumatic growth on cancer patients
Presenter: Dyta William
Session: Poster Display
Resources:
Abstract